Icatibant Brand Name– FIRAZYR
What is Icatibant
Icatibant (Firazyr) is a selective bradykinin B2 receptor antagonist used subcutaneously to treat acute attacks of hereditary angioedema (HAE) in adults.
HAE is a rare, genetic syndrome that causes subcutaneous and submucosal edema that can affect the upper airways, face, extremities, genitals, and gastrointestinal tract.
If an HAE attack involves the larynx or oropharynx, the attack can be life-threatening. Icatibant is administered upon recognition of an HAE attack.
If symptoms persist or relapse after at least 6 hours following the initial icatibant dose, additional doses may be administered (up to 3 doses in 24 hours).
Unlike ecallantide, icatibant may be administered by the patient after appropriate training by a healthcare professional.
The FDA approved icatibant in August 2011.
- ACE-inhibitor induced angioedema
- hereditary angioedema
For the treatment of acute attacks of hereditary angioedema (HAE)
- antibody formation
- elevated hepatic enzymes
- injection site reaction
- laboratory monitoring not necessary
- driving or operating machinery
- obstetric delivery
- Amlodipine; Benazepril
- Angiotensin-converting enzyme inhibitors
- Benazepril; Hydrochlorothiazide, HCTZ
- Captopril; Hydrochlorothiazide, HCTZ
- Enalapril, Enalaprilat
- Enalapril; Felodipine
- Enalapril; Hydrochlorothiazide, HCTZ
- Fosinopril; Hydrochlorothiazide, HCTZ
- Hydrochlorothiazide, HCTZ; Lisinopril
- Hydrochlorothiazide, HCTZ; Moexipril
- Hydrochlorothiazide, HCTZ; Quinapril
- Perindopril; Amlodipine
- Trandolapril; Verapamil